Currently, the gut is considered a primary site for the development of pathologies that modify brain functions such as neurodegenerative (Parkinson’s, Alzheimer’s, etc.) and metabolic (type 2 diabetes, obesity, etc.) disorders. Deciphering the mode of interaction between microbiota and the brain is a real original option to prevent (and maybe treat in the future) the establishment of gut-brain disfunctions and associated pathologies.
The Amazonian forests are home to a shrub, the camu-camu, whose fruit could be of great help in the fight against obesity and metabolic diseases. This is described in our latest study published with the A-Mansia R&D team in the journal Metabolites.
The enteric nervous system (ENS) plays a key role in controlling the gut-brain axis under normal and pathological conditions, such as type 2 diabetes. The discovery of intestinal actors, such as enterosynes, able to modulate the ENS-induced duodenal contraction is considered a pioneering approach.
In addition to their classical mode of action in the brain, circulating factors may modulate the release of reactive oxygen/nitrogen species (ROS/RNS) from endothelial cells that compose the blood-brain-barrier without entering the brain. Due to their high capacity to diffuse across membranes, ROS/RNS can reach neurons and modify their activity. This study investigates other mechanisms of actions in which beta-blockers may display a central effect without crossing the blood brain barrier.